Hangzhou Tigermed Consulting Co., Ltd. (3347.HK)
HKD 27.2
(1.68%)
HKD 27.2
(1.68%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.91 Billion CNY | 8.55% |
| 2022 | 2.42 Billion CNY | 14.92% |
| 2021 | 2.1 Billion CNY | 66.36% |
| 2020 | 1.26 Billion CNY | 25.53% |
| 2019 | 1.17 Billion CNY | 38.08% |
| 2018 | 683.63 Million CNY | 46.03% |
| 2017 | 473.45 Million CNY | 81.1% |
| 2016 | 256.65 Million CNY | 3.77% |
| 2015 | 255.6 Million CNY | 35.44% |
| 2014 | 188.15 Million CNY | 98.22% |
| 2013 | 96.29 Million CNY | 32.7% |
| 2012 | 72.54 Million CNY | 25.23% |
| 2011 | 58.17 Million CNY | 59.89% |
| 2010 | 36.87 Million CNY | 363.58% |
| 2009 | 7.79 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 439.24 Million CNY | 6.56% |
| 2024 Q3 | 336.51 Million CNY | -17.75% |
| 2024 Q1 | 352.86 Million CNY | 4.43% |
| 2023 Q2 | 874.19 Million CNY | 214.69% |
| 2023 Q3 | -403.94 Million CNY | -146.21% |
| 2023 Q4 | 1.57 Billion CNY | 490.13% |
| 2023 FY | - CNY | 8.55% |
| 2023 Q1 | 277.79 Million CNY | -74.36% |
| 2022 FY | - CNY | 14.92% |
| 2022 Q1 | 341.69 Million CNY | -83.55% |
| 2022 Q4 | 1.08 Billion CNY | 2198.59% |
| 2022 Q3 | -51.61 Million CNY | -106.58% |
| 2022 Q2 | 784.45 Million CNY | 129.58% |
| 2021 FY | - CNY | 66.36% |
| 2021 Q1 | -203.28 Million CNY | -143.25% |
| 2021 Q2 | 1 Billion CNY | 595.83% |
| 2021 Q3 | -962.55 Million CNY | -195.49% |
| 2021 Q4 | 2.07 Billion CNY | 315.77% |
| 2020 FY | - CNY | 25.53% |
| 2020 Q2 | 427.11 Million CNY | 305.32% |
| 2020 Q3 | 119.86 Million CNY | -71.94% |
| 2020 Q1 | 105.37 Million CNY | -59.65% |
| 2020 Q4 | 470.05 Million CNY | 292.17% |
| 2019 Q2 | 277.25 Million CNY | 47.66% |
| 2019 Q4 | 261.16 Million CNY | 8.84% |
| 2019 FY | - CNY | 38.08% |
| 2019 Q1 | 187.76 Million CNY | -24.48% |
| 2019 Q3 | 239.96 Million CNY | -13.45% |
| 2018 Q3 | 132.76 Million CNY | -28.43% |
| 2018 FY | - CNY | 46.03% |
| 2018 Q4 | 248.62 Million CNY | 87.27% |
| 2018 Q2 | 185.5 Million CNY | 75.09% |
| 2018 Q1 | 105.94 Million CNY | -42.86% |
| 2017 Q4 | 185.4 Million CNY | 71.15% |
| 2017 FY | - CNY | 81.1% |
| 2017 Q1 | 74.77 Million CNY | -7.28% |
| 2017 Q2 | 118.83 Million CNY | 58.93% |
| 2017 Q3 | 108.33 Million CNY | -8.84% |
| 2016 Q4 | 80.63 Million CNY | 82.04% |
| 2016 FY | - CNY | 3.77% |
| 2016 Q2 | 68.36 Million CNY | 25.68% |
| 2016 Q1 | 54.39 Million CNY | -34.41% |
| 2016 Q3 | 44.29 Million CNY | -35.2% |
| 2015 Q2 | 66.54 Million CNY | 49.36% |
| 2015 Q1 | 44.55 Million CNY | -35.59% |
| 2015 FY | - CNY | 35.44% |
| 2015 Q3 | 52.81 Million CNY | -20.63% |
| 2015 Q4 | 82.93 Million CNY | 57.04% |
| 2014 Q2 | 42.09 Million CNY | 23.45% |
| 2014 FY | - CNY | 98.22% |
| 2014 Q4 | 69.17 Million CNY | 54.15% |
| 2014 Q3 | 44.87 Million CNY | 6.6% |
| 2014 Q1 | 34.1 Million CNY | 40.2% |
| 2013 Q1 | 22.48 Million CNY | 15.66% |
| 2013 Q4 | 24.32 Million CNY | 19.29% |
| 2013 FY | - CNY | 32.7% |
| 2013 Q3 | 20.38 Million CNY | -26.35% |
| 2013 Q2 | 27.68 Million CNY | 23.11% |
| 2012 Q4 | 19.44 Million CNY | 16.83% |
| 2012 FY | - CNY | 25.23% |
| 2012 Q2 | 19.13 Million CNY | 19.7% |
| 2012 Q1 | 15.98 Million CNY | 13.09% |
| 2012 Q3 | 16.64 Million CNY | -13.02% |
| 2011 Q3 | 13.47 Million CNY | 0.0% |
| 2011 FY | - CNY | 59.89% |
| 2011 Q4 | 14.13 Million CNY | 4.9% |
| 2010 FY | - CNY | 363.58% |
| 2009 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Life Healthcare Group Limited | 27.68 Million HKD | -10424.833% |
| China Biotech Services Holdings Limited | -73.45 Million HKD | 4067.158% |